首页> 美国卫生研究院文献>Gynecologic Oncology Research and Practice >Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001
【2h】

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001

机译:治疗人乳头瘤病毒相关癌症的治疗选择-新型免疫疫苗:ADXS11–001

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector Listeria monocytogenes (Lm) activates innate and adaptive immune responses and is expected to offer immunologic advantages. Axalimogene filolisbac (AXAL or ADXS11–001) is a novel immunotherapeutic based on the live, irreversibly attenuated Lm fused to the nonhemolytic fragment of listeriolysin O (Lm-LLO) and secretes the Lm-LLO-HPV E7 fusion protein targeting HPV-positive tumors. Herein are reported the development and recent results of various clinical trials in patients with HPV-associated cervical, head and neck, and anal cancers.
机译:尽管有多种治疗方法,但患有晚期,复发或转移性人乳头瘤病毒(HPV)相关癌症的患者的生存率欠佳。最近开发的细菌载体单核细胞增生李斯特氏菌(Lm)激活先天性和适应性免疫反应,并有望提供免疫学优势。 Axalimogene filolisbac(AXAL或ADXS11-001)是一种新型的免疫疗法,其基于与李斯特菌溶血素O(Lm-LLO)的非溶血片段融合的,不可逆减毒的活Lm,并分泌针对HPV阳性肿瘤的Lm-LLO-HPV E7融合蛋白。本文报道了在HPV相关的宫颈癌,头颈癌和肛门癌患者中各种临床试验的进展和最新结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号